IOM Proposals for Overhaul at CIRM Win High Marks
By David Jensen,
California Stem Cell Report
| 12. 07. 2012
[Quotes CGS's Marcy Darnovsky]
The Institute of Medicine's recommendations for major changes at the California stem cell agency today received generally high marks from independent observers and critics.
Many of the proposals echoed suggestions from California's Little Hoover Commission, the state's good government agency. Asked for comment, Stuart Drown, the commission's executive director, said,
“The institute’s recommendations for much-needed changes to CIRM’s governance structure to provide greater efficiency, clarity and accountability reinforce the recommendations the Little Hoover Commission made in 2009."
He continued,
“Then and now, the Commission’s recommendations are aimed at improving
CIRM’s ability to meet its goals for the good of all who can benefit
from stem cell research, and to ensure that California taxpayers’
dollars are put to their most efficient use to that end.”
The California Stem Cell Report also asked the agency's first president,
Zach Hall, for his thoughts. Here is the full text of what Hall, who
was one of the peer reviewers on the IOM study, had to say,
“The IOM Committee and its staff have done an impressive job. The
report recognizes the scientific value and...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...